Profound Medical (NASDAQ: PROF; TSX: PRN) announced preliminary unaudited revenues for the third quarter of 2026. The company indicated that its:
- Total revenue is expected to be in the range of $9.8 million to $10.0 million.
- Year-over-year revenue growth is expected to be 85% to 89% compared with $5.3 million in the third quarter of 2025.
- Sequential quarter-over-quarter revenue growth is expected to be 292% to 300% compared with $2.5 million in the second quarter of 2026.
- Expected revenue is 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million.
- Q3-2026 gross margin is again expected to exceed 70%, reflecting continued progress in the company’s commercial operations and scale.
“The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound, reflecting the strong commercial momentum building behind our technology,” said Arun Menawat, Profound’s CEO and Chairman, in a statement.
Dr. Menawat added, “With preliminary revenue of approximately $9.8 million to $10.0 million and gross margin expected to exceed 70%, we believe the third quarter represents an important step in the continued expansion of our commercial business. We remain focused on supporting customer adoption, increasing utilization of our installed base, and building a profitable growth company over the long-term.”
Profound noted the figures are preliminary and unaudited, and actual revenues may differ. In addition, consensus estimates are based on the work of third-party analysts, and the company does not endorse, adopt, or control them. Profound intends to report full third quarter 2026 financial results after market close on Thursday, November 5th.
